JYJie Yu

Jie Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jie Yu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Chunxia Ou

    Laboratory of Molecular Cardiology, Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China

    2 shared publications
  • Jie Hu

    Laboratory of Molecular Cardiology, Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China

    2 shared publications
  • Yan Wang

    Laboratory of Molecular Cardiology, Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China

    2 shared publications
  • Chao Wu

    Laboratory of Molecular Cardiology, Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China

    1 shared publication
  • Guihu Sun

    Laboratory of Molecular Cardiology, Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China

    1 shared publication
  • Huaiyao Wang

    Laboratory of Molecular Cardiology, Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China

    1 shared publication

Latest Publications

  • Open Access

    Integrated bioinformatics analysis and mouse validation identify C7 and MFAP4 as candidate genes associated with type 2 diabetes and atherosclerosis

    by Ling Wang, Yu Chen, Peng Ding, Huaiyao Wang, Chao Wu, Peizheng Li, Chunxia Ou, Zuojing Xie, Jiannan Jin, Jie Hu, et al.

  • miRNA-146a-5p Inhibits Hypoxia-Induced Myocardial Fibrosis Through EndMT

    by Yan Wang, Jie Yu, Chunxia Ou, Yue Zhao, Lixing Chen, Wenke Cai, Huawei Wang, Shiying Huang, Jie Hu, Guihu Sun, et al.

    Cardiac Vascular disease particularly myocardial infarction (MI) is a threat to health worldwide. microRNAs (miRNAs) have been shown to regulate myocardial fibrosis. Therefore, it is potential to investigate the mechanism of miRNA and fibrosis following myocardial infarction. Hypoxia human cardiac microvascular endothelial cells (HCMECs) were selected for the vitro experimental model. The miR-146a-5p expression was tested via RT-qPCR. The level of endothelial-to-mesenchymal transition (EndMT) and fibrosis markers were detected by Western blotting and immunofluorescence. Then, the inflammation, cell viability and apoptosis were investigated. The target was predicted by an online database and verified by a dual-luciferase activity assay. An MI mouse model was created to validate that miR-146a-5p regulates cardiac fibrosis in vivo. MI mouse was transfected with miR-146a-5p lentivirus. Subsequently, its effect on cardiac fibrosis of infarcted hearts was assessed by In situ hybridization (ISH), Immunohistochemistry (IHC), Triphenylterazolium chloride (TTC) staining and Masson staining. Herein, we confirmed that miR-146a-5p was down-regulated in hypoxia HCMECs. Overexpression of miR-146a-5p inhibited hypoxia-induced cardiac fibrosis following myocardial infarction by inhibiting EndMT in HCMECs. Thioredoxin-interacting protein (TXNIP) was a target that was negatively regulated by miR-146a-5p. Up-regulation of miR-146a-5p inhibited cardiac fibrosis via regulating EndMT by targeting TXNIP, and it also regulated EndMT to inhibit cardiac fibrosis in vivo.